{"disease":{"id":"melanoma-stage-iiic","name":"melanoma stage iiic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01274338","title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1673,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03677739","title":"Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1160,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT01989572","title":"Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":815,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03819296","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03028948","title":"Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":485,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT07259304","title":"Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT01134614","title":"Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":245,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02419495","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":221,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02068586","title":"Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":210,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT04067960","title":"Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04462406","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT02304458","title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT04990726","title":"Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01708941","title":"Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01258855","title":"Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06708455","title":"Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":65,"lead_sponsor_name":"Rapa Therapeutics LLC","has_results":false},{"nct_id":"NCT03707574","title":"Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study","phase":"","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01480154","title":"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04708418","title":"A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02129075","title":"A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03554083","title":"Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":59,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02231775","title":"Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":58,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05039801","title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02519322","title":"Neoadjuvant and Adjuvant Checkpoint Blockade","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02910700","title":"Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04771520","title":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01835145","title":"Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02965716","title":"Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03769155","title":"VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":41,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT01638533","title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04940299","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03590054","title":"Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT01303341","title":"Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01955460","title":"Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01460875","title":"Recombinant Interferon Alfa-2b in Treating Patients With Melanoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"William Carson","has_results":true},{"nct_id":"NCT01902173","title":"Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03396952","title":"Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT05098210","title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT02320305","title":"MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02097225","title":"Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01840007","title":"Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT02857374","title":"Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT01727076","title":"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06556004","title":"Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"University of Chile","has_results":false},{"nct_id":"NCT03021460","title":"Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04902040","title":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02500576","title":"Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT01940809","title":"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}